abstract: OBJECTIVE: To investigate nonpermanent inferior vena cava (IVC) filter in the prevention of perioperative @entity1151 ( @entity1151 ) in @entity1 of @entity174 with @entity1150 ( @entity1150 ). METHODS: Lower extremity or pelvic @entity174 @entity1 with lower extremity @entity1150 hospitalized in our hospital from January 2003 to October 2014 were retrospectively analyzed. Data was analyzed for age, gender, position of @entity174 , position of proximal of @entity715 , indications of placement, complications, retrieval rate, and rate of entrapped filter clot. @entity1 who underwent IVC filter placement were selected as the filter group. The @entity1 who did not perform IVC filter placement after 2008 and the cases between January 2003 and December 2007 were selected as control group 1 and control group 2, respectively. The incidence of perioperative symptomatic @entity1151 and mortality were analyzed. RESULTS: A total of 2763 cases complicated with @entity1150 underwent orthopedic surgery between January 2003 and October 2014. 823 nonpermanent filters were inserted. All filters were successfully deployed with no major complications. After a mean 14.2 days indwelling time, all of temporary filters were removed. Retrieval was attempted in 556 @entity1 with retrievable filters and was successful in 545 (98%); mean indwelling time was 16.3 days. The total retrieval rate was 90%. The incidence of @entity1151 in the filter group was significantly lower compared with the two control groups. Among the @entity1 who received chemical anticoagulant therapy, the incidence of @entity1151 in filter group, control group 1 and control group 2 were 0.14%, 1.60% and 2.10%, respectively. The incidence of @entity1151 in filter group was also significant lower compared with control groups. CONCLUSION: Nonpermanent IVC filter placement seems like to be a safe and effective method for preventing perioperative symptomatic and fatal @entity1151 in @entity174 @entity1 with @entity1150 in the present retrospective study.

title: Evaluation of nonpermanent inferior vena cava filter placement in @entity1 with @entity1150 after XXXX : A single-center retrospective study.

entities_list: @entity1 :: ('9606', 'Species') :: ['Patients', 'patients']

entities_list: @entity174 :: ('MESH:D050723', 'Disease') :: ['lower extremity and/or pelvic bone fracture', 'fracture', 'bone fracture']

entities_list: @entity1151 :: ('MESH:D011655', 'Disease') :: ['PE', 'pulmonary embolism']

entities_list: @entity1150 :: ('MESH:D020246', 'Disease') :: ['deep vein thrombosis', 'DVT']

entities_list: @entity715 :: ('MESH:D013927', 'Disease') :: ['thrombosis']

answer: @entity174 :: (MESH:D050723,Disease) :: ['lower extremity fracture']


abstract: OBJECTIVE: To investigate nonpermanent inferior vena cava (IVC) filter in the prevention of perioperative @entity1151 ( @entity1151 ) in @entity1 of @entity174 with @entity1150 ( @entity1150 ). METHODS: Lower extremity or pelvic @entity174 @entity1 with lower extremity @entity1150 hospitalized in our hospital from January 2003 to October 2014 were retrospectively analyzed. Data was analyzed for age, gender, position of @entity174 , position of proximal of @entity715 , indications of placement, complications, retrieval rate, and rate of entrapped filter clot. @entity1 who underwent IVC filter placement were selected as the filter group. The @entity1 who did not perform IVC filter placement after 2008 and the cases between January 2003 and December 2007 were selected as control group 1 and control group 2, respectively. The incidence of perioperative symptomatic @entity1151 and mortality were analyzed. RESULTS: A total of 2763 cases complicated with @entity1150 underwent orthopedic surgery between January 2003 and October 2014. 823 nonpermanent filters were inserted. All filters were successfully deployed with no major complications. After a mean 14.2 days indwelling time, all of temporary filters were removed. Retrieval was attempted in 556 @entity1 with retrievable filters and was successful in 545 (98%); mean indwelling time was 16.3 days. The total retrieval rate was 90%. The incidence of @entity1151 in the filter group was significantly lower compared with the two control groups. Among the @entity1 who received chemical anticoagulant therapy, the incidence of @entity1151 in filter group, control group 1 and control group 2 were 0.14%, 1.60% and 2.10%, respectively. The incidence of @entity1151 in filter group was also significant lower compared with control groups. CONCLUSION: Nonpermanent IVC filter placement seems like to be a safe and effective method for preventing perioperative symptomatic and fatal @entity1151 in @entity174 @entity1 with @entity1150 in the present retrospective study.

title: Evaluation of nonpermanent inferior vena cava filter placement in @entity1 with XXXX after @entity174 : A single-center retrospective study.

answer: @entity1150 :: (MESH:D020246,Disease) :: ['deep venous thrombosis']


abstract: OBJECTIVE: To investigate nonpermanent inferior vena cava (IVC) filter in the prevention of perioperative @entity1151 ( @entity1151 ) in @entity1 of @entity174 with @entity1150 ( @entity1150 ). METHODS: Lower extremity or pelvic @entity174 @entity1 with lower extremity @entity1150 hospitalized in our hospital from January 2003 to October 2014 were retrospectively analyzed. Data was analyzed for age, gender, position of @entity174 , position of proximal of @entity715 , indications of placement, complications, retrieval rate, and rate of entrapped filter clot. @entity1 who underwent IVC filter placement were selected as the filter group. The @entity1 who did not perform IVC filter placement after 2008 and the cases between January 2003 and December 2007 were selected as control group 1 and control group 2, respectively. The incidence of perioperative symptomatic @entity1151 and mortality were analyzed. RESULTS: A total of 2763 cases complicated with @entity1150 underwent orthopedic surgery between January 2003 and October 2014. 823 nonpermanent filters were inserted. All filters were successfully deployed with no major complications. After a mean 14.2 days indwelling time, all of temporary filters were removed. Retrieval was attempted in 556 @entity1 with retrievable filters and was successful in 545 (98%); mean indwelling time was 16.3 days. The total retrieval rate was 90%. The incidence of @entity1151 in the filter group was significantly lower compared with the two control groups. Among the @entity1 who received chemical anticoagulant therapy, the incidence of @entity1151 in filter group, control group 1 and control group 2 were 0.14%, 1.60% and 2.10%, respectively. The incidence of @entity1151 in filter group was also significant lower compared with control groups. CONCLUSION: Nonpermanent IVC filter placement seems like to be a safe and effective method for preventing perioperative symptomatic and fatal @entity1151 in @entity174 @entity1 with @entity1150 in the present retrospective study.

title: Evaluation of nonpermanent inferior vena cava filter placement in XXXX with @entity1150 after @entity174 : A single-center retrospective study.

answer: @entity1 :: (9606,Species) :: ['patients']


abstract: The genetic etiology of @entity0 has not been fully elucidated. Although germline mutations of high-penetrance genes such as @entity6069 are implicated in development of @entity0 , at least half of all @entity0 families are not linked to these genes. To identify a comprehensive spectrum of genetic factors for @entity0 in a Chinese population, we performed an analysis of germline mutations in 2,165 coding exons of 152 genes associated with @entity4310 using next-generation sequencing (NGS) in 99 @entity0 @entity1 from families of @entity5 @entity1 regardless of @entity5 types. Forty-two deleterious germline mutations were identified in 21 genes of 34 @entity1 , including 18 (18.2%) @entity5345 or @entity2674 mutations, 3 (3%) @entity876 mutations, 5 (5.1%) DNA mismatch repair gene mutations, 1 (1%) @entity5962 mutation, 6 (6.1%) @entity11807 pathway gene mutations, and 9 (9.1%) mutations in other genes. Of seven @entity1 who carried mutations in more than one gene, 4 were @entity5345 /2 mutation carriers, and their average onset age was much younger than @entity1 with only @entity6069 mutations. Almost all identified high-penetrance gene mutations in those families fulfill the typical phenotypes of @entity4310 listed in the National @entity5 Network (NCCN) guidelines, except two @entity876 and three mismatch repair gene mutations. Furthermore, functional studies of @entity23151 germline mutations confirmed the association between @entity23151 mutation and tumorigenesis, and segregation analysis suggested antagonism between @entity5345 and @entity23151 . We also identified a lot of low-penetrance gene mutations. Although the clinical significance of those newly identified low-penetrance gene mutations has not been fully appreciated yet, these new findings do provide valuable epidemiological information for the future studies. Together, these findings highlight the importance of genetic testing based on NCCN guidelines and a multi-gene analysis using NGS may be a supplement to traditional genetic counseling.

title: Identification of a comprehensive spectrum of genetic factors for XXXX in a chinese population by next-generation sequencing.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity0 :: ('MESH:D001943', 'Disease') :: ['hereditary breast cancers', 'breast cancer', 'hereditary breast cancer']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['cancer', 'Comprehensive Cancer']

entities_list: @entity4310 :: ('MESH:D009386', 'Disease') :: ['hereditary cancer', 'hereditary cancer syndromes']

entities_list: @entity11807 :: ('MESH:D005199', 'Disease') :: ['Fanconi anemia']

answer: @entity0 :: (MESH:D001943,Disease) :: ['hereditary breast cancer']


abstract: INTRODUCTION: A major problem in cartilage repair is the lack of chondrogenic cells migrating from healthy tissue into defects. Cartilage is essentially avascular and therefore its healing is not considered to involve mononuclear cells. Peripheral blood derived mononuclear cells (PBMC) offer a readily available autologous cell source for clinical use and therefore this study was designed to evaluate the effects of PBMCs on chondrocytes and cartilage. METHODS: @entity1 primary chondrocytes and cartilage tissue explants were taken from @entity1 undergoing total knee replacement (n   =   17). Peripheral blood samples were obtained from healthy volunteers (n   =   12) and mononuclear cells were isolated by density-gradient centrifugation. Cell migration and chemokinetic potential were measured using a scratch assay, xCELLigence and CyQuant assay. PCR array and quantitative PCR was used to evaluate mRNA expression of 87 cell motility and/or chondrogenic genes. RESULTS: The chondrocyte migration rate was 2.6 times higher at 3 hour time point (p   <   0.0001) and total number of migrating chondrocytes was 9.7 times higher (p   <   0.0001) after three day indirect PBMC stimulus and 8.2 times higher (p   <   0.0001) after three day direct co-culture with PBMCs. A cartilage explant model confirmed that PBMCs also exert a chemokinetic role on ex vivo tissue. PBMC stimulation was found to significantly upregulate the mRNA levels of 2 chondrogenic genes; collagen type II ( @entity794 600-fold, p   <   0.0001) and @entity1935 ( @entity1935 30-fold, p   <   0.0001) and the mRNA levels of 7 genes central in cell motility and migration were differentially regulated by 24h PBMC stimulation. CONCLUSION: The results support the concept that PBMC treatment enhances chondrocyte migration without suppressing the chondrogenic phenotype possibly via mechanistic pathways involving @entity1495 and @entity442 . In the future, peripheral blood mononuclear cells could be used as an autologous point-ofcare treatment to attract native chondrocytes from the diseased tissue to aid in cartilage repair.

title: Peripheral blood derived mononuclear cells enhance osteoarthritic XXXX chondrocyte migration.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'Human']

answer: @entity1 :: (9606,Species) :: ['human']


abstract: INTRODUCTION: To evaluate the prognostic value of gross @entity5 volume (TV) in @entity1 with locally recurrent, nonmetastatic @entity189 . METHODS: Between 2001 and 2012, 291 consecutive @entity1 with locally recurrent, nonmetastatic @entity189 underwent salvage IMRT were retrospectively reviewed. The correlations between TV and recurrent T classification were analyzed. Survival analyses were performed. Receiver operating characteristic (ROC) curves were calculated to identify cut-off point of TV. The Akaike information criterion and Harrell's concordance index (c-index) were utilized to test the prognostic value. RESULTS: The median TV significantly increased with advancing recurrent T classification (P<0.001). The 5-year overall survival rate was 33.2% for the entire cohort. On multivariate analysis, TV was an independent negative prognostic factor for distant @entity3 -free survival (hazard ratio =1.013, P =0.003), overall survival (hazard ratio = 1.015, P<0.001) and @entity137 -related @entity204 (hazard ratio = 1.014, P<0.001). The 5-year overall survival rates were 63.1% and 20.8% for @entity1 with a TV < 22 cm3 and TV >= 22 cm3, respectively (P < 0.001). In @entity1 with TV <22 cm3, locoregional failure is the leading cause of @entity204 . In @entity1 with TV>= 22 cm3, distant @entity3 rate is higher and occurred within short term after local recurrence; meanwhile, radiation-induced injuries became more common and led to half of deaths in this group. The Akaike information criterion and c-index analyses indicated that the predictive ability of recurrent T classification improved when combined with TV. CONCLUSIONS: Our data suggests TV is a significant prognostic factor for predicting the distant @entity3 , overall survival and @entity137 -related @entity204 of @entity1 with locally recurrent, nonmetastatic @entity189 after salvage IMRT. TV should be considered when designing personalized salvage treatments for these @entity1 . For @entity1 with bulky local recurrent @entity5 , radiation may need to be de-emphasized in favor of systemic treatment or best supportive care.

title: Prognostic significance of @entity5 volume in locally recurrent XXXX treated with salvage intensity-modulated radiotherapy.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'patient']

entities_list: @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicity']

entities_list: @entity189 :: ('MESH:D002277', 'Disease') :: ['nasopharyngeal carcinoma']

entities_list: @entity3 :: ('MESH:D009362', 'Disease') :: ['metastasis']

answer: @entity189 :: (MESH:D002277,Disease) :: ['nasopharyngeal carcinoma']


abstract: INTRODUCTION: To evaluate the prognostic value of gross @entity5 volume (TV) in @entity1 with locally recurrent, nonmetastatic @entity189 . METHODS: Between 2001 and 2012, 291 consecutive @entity1 with locally recurrent, nonmetastatic @entity189 underwent salvage IMRT were retrospectively reviewed. The correlations between TV and recurrent T classification were analyzed. Survival analyses were performed. Receiver operating characteristic (ROC) curves were calculated to identify cut-off point of TV. The Akaike information criterion and Harrell's concordance index (c-index) were utilized to test the prognostic value. RESULTS: The median TV significantly increased with advancing recurrent T classification (P<0.001). The 5-year overall survival rate was 33.2% for the entire cohort. On multivariate analysis, TV was an independent negative prognostic factor for distant @entity3 -free survival (hazard ratio =1.013, P =0.003), overall survival (hazard ratio = 1.015, P<0.001) and @entity137 -related @entity204 (hazard ratio = 1.014, P<0.001). The 5-year overall survival rates were 63.1% and 20.8% for @entity1 with a TV < 22 cm3 and TV >= 22 cm3, respectively (P < 0.001). In @entity1 with TV <22 cm3, locoregional failure is the leading cause of @entity204 . In @entity1 with TV>= 22 cm3, distant @entity3 rate is higher and occurred within short term after local recurrence; meanwhile, radiation-induced injuries became more common and led to half of deaths in this group. The Akaike information criterion and c-index analyses indicated that the predictive ability of recurrent T classification improved when combined with TV. CONCLUSIONS: Our data suggests TV is a significant prognostic factor for predicting the distant @entity3 , overall survival and @entity137 -related @entity204 of @entity1 with locally recurrent, nonmetastatic @entity189 after salvage IMRT. TV should be considered when designing personalized salvage treatments for these @entity1 . For @entity1 with bulky local recurrent @entity5 , radiation may need to be de-emphasized in favor of systemic treatment or best supportive care.

title: Prognostic significance of XXXX volume in locally recurrent @entity189 treated with salvage intensity-modulated radiotherapy.

answer: @entity5 :: (MESH:D009369,Disease) :: ['tumor']


abstract: BACKGROUND: Caudate lobe liver metastases occur commonly in @entity1 with @entity5 . It is unknown, however, how these lesions respond to regional therapy and how their presence impacts outcomes. We reviewed our experience treating these lesions using transarterial chemoembolization (TACE). METHODS: We reviewed radiographic response to TACE in 86 @entity1 with metastatic @entity5 to the liver. We determined the impact of caudate lesions on outcomes in comparison to the cohort of @entity1 without caudate lesions, as well as response of caudate lesions to TACE versus lesions elsewhere in the liver. RESULTS: Caudate lesions were identified in 45 (52%) @entity1 . All @entity1 had disease in other liver segments. Only seven caudate lesions (12.3%) had a radiographic response to TACE, whereas 82% of lesions elsewhere in the liver demonstrated a response. The presence or absence of a caudate lesion did not impact the overall radiographic (82.2% vs. 82.9%), symptomatic (64.4% vs. 56.1%), or biochemical (97.6% vs. 88.9%) response to TACE (P   >   0.1 for all). However, median overall survival was reduced in those presenting with caudate lesions (87.1 vs. 45.6  months, P   =   0.031). CONCLUSIONS: Metastatic @entity5 to the caudate lobe respond poorly to TACE. Symptomatic or threatening caudate lobe lesions should be considered for palliative resection in spite of additional inoperable liver metastases.

title: Transarterial chemoembolization is ineffective for XXXX metastatic to the caudate lobe: a single institution review.

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['neuroendocrine tumors']

answer: @entity5 :: (MESH:D009369,Disease) :: ['neuroendocrine tumors']


abstract: OBJECTIVE: To determine the long-term results of @entity1 undergoing transcatheter coil embolization for the treatment of acute @entity548 . METHODS: @entity1 undergoing angiography for suspected @entity694 between January 2002 and December 2012 were reviewed (average age, 60   years; 38.4% male). Baseline, procedural and outcome parameters were recorded following the Society of Interventional Radiology guidelines. Primary outcome measures included early (<30   days) and delayed (>30   days) rebleeding events and adverse procedure-related complication. Average follow-up time was 996   days (median, 232   days; range, 30-3663   days). RESULTS: One or multiple sites of @entity548 were identified in 40 cases. Coil embolization was performed in 39 @entity1 , 26 (66.7%, 26/39) of whom were treated successfully without technical/clinical failure (n   =   12) or loss to follow-up (n   =   1). Three @entity1 (11.5%, 3/26) rebled in the early period within 30 days; one @entity1 went on to hemicolectomy. Four @entity1 (15.3%, 4/26) experienced delayed rebleeding after 30   days; two of whom also underwent hemicolectomy. No major complication occurred. One minor complication of @entity1347 was seen in the clinical failure group. One case of asymptomatic ischaemia was identified on a @entity1 undergoing pre-operative colonoscopy for elective bowel resection. No instances of ischaemic stricture were seen. All-cause mortality of successfully treated and all @entity1 at 1   year was 31% (8/26) and 30% (12/40), respectively. CONCLUSION: Transcatheter coil embolization is a durable treatment option with a technical and clinical success rate of 67% in the setting of acute @entity548 . A modest level of rebleeding was seen among successfully treated @entity1 in both the early and delayed periods; in the majority of @entity1 , embolization proved to be definitive therapy. ADVANCES IN KNOWLEDGE: Transcatheter coil embolization is a durable and potentially definitive therapy in the management of acute @entity548 .

title: Long-term results of microcoil embolization for XXXX : how common is rebleeding?

entities_list: @entity1 :: ('9606', 'Species') :: ['Patients', 'patients', 'patient']

entities_list: @entity1347 :: ('MESH:C537775', 'Disease') :: ['short segment arterial dissection']

entities_list: @entity694 :: ('MESH:D003110', 'Disease') :: ['colonic bleeding']

entities_list: @entity548 :: ('MESH:D006470', 'Disease') :: ['bleeding', 'colonic haemorrhage']

answer: @entity548 :: (MESH:D006470,Disease) :: ['colonic haemorrhage']


abstract: @entity5 is on the declining trend in India according to the population-based registries; yet it continues to be a major public health problem for @entity1 in India. Multifactorial causation, potential for prevention, and the sheer threat it poses make @entity5 an important disease for in-depth studies, as has been attempted by this paper. This paper attempts to review the available knowledge regarding the epidemiology and pattern of @entity5 ; types of HPV ( @entity1082 ) prevalent among @entity5 @entity1 and among @entity1 in general, high-risk groups such as commercial sex workers, and @entity645 ( @entity1 immunodeficiency virus)-positive @entity1 ; and the role of the national program on @entity5 in control efforts. The peak age of incidence of @entity5 is 55-59 years, and a considerable proportion of @entity1 report in the late stages of disease. Specific types of oncogenic @entity1799 , 18 have been identified in @entity1 with @entity5 . Other epidemiological risk factors are early age at marriage, multiple sexual partners, @entity2099 , poor genital hygiene, @entity3147 , use of @entity7280 , and lack of awareness. A multipronged approach is necessary which can target areas of high prevalence identified by registries with a combination of behavior change communication exercises and routine early screening with VIA. Sensitizing the @entity1 of the area, including menfolk, is necessary to increase uptake levels. Vaccination against types 16 and 18 can also be undertaken after taking into confidence all stakeholders, including the parents of adolescent @entity1 . Preventing and treating @entity5 and reducing the burden are possible by targeting resources to the areas with high prevalence.

title: Epidemiology of XXXX with special focus on India.

entities_list: @entity1 :: ('9606', 'Species') :: ['women', 'human', 'patients', 'girls', 'people']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['cancer', 'cervical cancer', 'Cervical cancer']

entities_list: @entity2099 :: ('MESH:D011254', 'Disease') :: ['multiple pregnancies']

entities_list: @entity1082 :: ('10566', 'Species') :: ['human papilloma virus']

entities_list: @entity3147 :: ('MESH:D044342', 'Disease') :: ['malnutrition']

entities_list: @entity7280 :: ('MESH:D003276', 'Chemical') :: ['oral contraceptives']

answer: @entity5 :: (MESH:D009369,Disease) :: ['cervical cancer']


abstract: @entity8 is an important cause of end @entity177 . Rarely, these @entity1 may present with @entity548 caused by @entity8 . The aim of this study was to report a rare case of a @entity1 who arrived at the emergency department with @entity8 presenting with acute @entity490 and @entity548 . A 58-year-old male with @entity177 was admitted to the emergency department with acute @entity490 and @entity548 . The @entity1 was admitted to the Department of Surgery with diagnosis of acute abdomen and perirenal @entity1410 . Although the @entity1 was on conservative treatment, his symptoms did not improve and the @entity1 was operated emergently. During exploration, there was bleeding from the right @entity8767 , which was 30*20 cm in dimension. The @entity1 underwent nephrectomy and drainage of the @entity1410 , and was discharged on the fifth postoperative day without any problems. Bleeding due to rupture of a cyst in @entity8 occurs rarely but it may be life threatening. Although conservative methods are often preferable in treatment, surgery can be life saving for @entity1 in whom the clinical situation does not improve.

title: Acute abdomen and @entity548 caused by spontaneous rupture of @entity8 in XXXX .

entities_list: @entity8 :: ('MESH:D007674', 'Disease') :: ['rupture of the renal cyst', 'Autosomal dominant polycystic kidney disease', 'autosomal dominant polycystic kidney disease']

entities_list: @entity548 :: ('MESH:D006470', 'Disease') :: ['hemorrhagic shock']

entities_list: @entity177 :: ('MESH:D051437', 'Disease') :: ['stage renal failure', 'chronic renal failure']

entities_list: @entity490 :: ('MESH:D015746', 'Disease') :: ['abdominal pain']

entities_list: @entity8767 :: ('MESH:D007690', 'Disease') :: ['polycystic kidney']

answer: @entity8 :: (MESH:D007674,Disease) :: ['autosomal dominant polycystic kidney disease']


abstract: @entity8 is an important cause of end @entity177 . Rarely, these @entity1 may present with @entity548 caused by @entity8 . The aim of this study was to report a rare case of a @entity1 who arrived at the emergency department with @entity8 presenting with acute @entity490 and @entity548 . A 58-year-old male with @entity177 was admitted to the emergency department with acute @entity490 and @entity548 . The @entity1 was admitted to the Department of Surgery with diagnosis of acute abdomen and perirenal @entity1410 . Although the @entity1 was on conservative treatment, his symptoms did not improve and the @entity1 was operated emergently. During exploration, there was bleeding from the right @entity8767 , which was 30*20 cm in dimension. The @entity1 underwent nephrectomy and drainage of the @entity1410 , and was discharged on the fifth postoperative day without any problems. Bleeding due to rupture of a cyst in @entity8 occurs rarely but it may be life threatening. Although conservative methods are often preferable in treatment, surgery can be life saving for @entity1 in whom the clinical situation does not improve.

title: Acute abdomen and @entity548 caused by spontaneous rupture of XXXX in @entity8 .

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'patient']

answer: @entity8 :: (MESH:D007674,Disease) :: ['renal cyst']


abstract: @entity8 is an important cause of end @entity177 . Rarely, these @entity1 may present with @entity548 caused by @entity8 . The aim of this study was to report a rare case of a @entity1 who arrived at the emergency department with @entity8 presenting with acute @entity490 and @entity548 . A 58-year-old male with @entity177 was admitted to the emergency department with acute @entity490 and @entity548 . The @entity1 was admitted to the Department of Surgery with diagnosis of acute abdomen and perirenal @entity1410 . Although the @entity1 was on conservative treatment, his symptoms did not improve and the @entity1 was operated emergently. During exploration, there was bleeding from the right @entity8767 , which was 30*20 cm in dimension. The @entity1 underwent nephrectomy and drainage of the @entity1410 , and was discharged on the fifth postoperative day without any problems. Bleeding due to rupture of a cyst in @entity8 occurs rarely but it may be life threatening. Although conservative methods are often preferable in treatment, surgery can be life saving for @entity1 in whom the clinical situation does not improve.

title: Acute abdomen and XXXX caused by spontaneous rupture of @entity8 in @entity8 .

answer: @entity548 :: (MESH:D006470,Disease) :: ['hemorrhagic shock']


abstract: OBJECTIVE: Non-operative management of @entity3511 has recently become more common. Especially non-operative treatment of blunt @entity1661 is gaining wide acceptance. In this study, the efficacy of non-operative treatment in @entity1661 (blunt penetrating) is discussed. MATERIAL AND METHODS: All @entity1 who received treatment due to @entity1661 from November 2008 to January 2013 were retrospectively analyzed. The demographic characteristics, @entity130 , injured organ, type of treatment (operative vs. nonoperative) and mortality data were evaluated. RESULTS: The study includes 115 @entity1 treated for @entity1661 in our department. The mechanism of @entity130 was stab wounds in 60%, blunt @entity1661 in 23.5% and gunshot wounds in 16.5%. Forty-two @entity1 (36.5%) were operated for hemodynamic instability and/or @entity298 on admission. The remaining 63.5% of @entity1 (n=73) were treated nonoperatively, 10 of whom required laparotomy during follow-up. The remaining 63 @entity1 were treated with non-operative management. The success rate for non-operative treatment was 86.3% and there was no difference in terms of the types of @entity130 . The mortality rate was 4.3% (n= 5) in the whole series, but there were no deaths among the @entity1 who had received non-operative treatment. In the whole @entity1 group 54.2% (n=63) were treated nonoperatively. CONCLUSION: Nonoperative treatment in @entity1661 is safe and effective. @entity1 with clinical stability and normal physical examination findings can be treated nonoperatively with close monitoring.

title: Conservative management of XXXX .

entities_list: @entity1661 :: ('MESH:D000008', 'Disease') :: ['abdominal trauma']

entities_list: @entity3511 :: ('MESH:D000007', 'Disease') :: ['abdominal injuries']

entities_list: @entity298 :: ('MESH:D010538', 'Disease') :: ['peritonitis']

entities_list: @entity130 :: ('MESH:D014947', 'Disease') :: ['injuries', 'type of injury', 'trauma']

answer: @entity3511 :: (MESH:D000007,Disease) :: ['abdominal injuries']


abstract: OBJECTIVE: We aimed to investigate the relationship between the horizontal @entity5 diameter and prognosis. MATERIAL AND METHODS: @entity1 ' records were analyzed retrospectively. @entity1 data, including age, gender, vertical penetration, anatomic location, differentiation of the @entity5 , @entity5 node @entity3 (TNM) stage, survival rate, and disease-free survival, were analyzed to find out if there was any correlation with horizontal @entity5 diameter. RESULTS: A total of 439 @entity14 @entity1 were enrolled. @entity1 were stratified into two groups according to the horizontal @entity5 diameter ( <=4.5 cm vs. >4.5 cm). Poorly differentiated @entity5 were significantly larger than other differentiation groups (p=0.003). The horizontal diameter increased with increase in T-stage (p<0.001). Similarly, the number of positive lymph nodes increased significantly as the size of the horizontal @entity5 diameter increased (p<0.001). The relationship between TNM staging and the horizontal diameter of @entity5 in both groups was examined, and it was found that the progression of @entity5 stage was accompanied by increased horizontal diameter (p<0.001). It was also found that the horizontal @entity5 diameter was not correlated with local recurrence (p=0.063). However, distant @entity3 was higher in @entity1 with a @entity5 larger than 4.5 cm (p=0.02). Although the disease-free survival was shorter in @entity1 with a horizontal @entity5 diameter more than 4.5 cm, the difference was not statistically significant. CONCLUSION: There is a significant relation between horizontal diameter of the @entity5 and depth of the @entity5 , lymph node involvement, overall survival, and distant @entity3 . Horizontal diameter of the @entity5 can possibly be used as a prognostic factor in @entity14 @entity1 .

title: Can horizontal diameter of XXXX help predict prognosis?

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor', 'tumors']

entities_list: @entity1 :: ('9606', 'Species') :: ['Patients', 'patients', 'Patient']

entities_list: @entity14 :: ('MESH:D015179', 'Disease') :: ['colorectal cancer']

entities_list: @entity3 :: ('MESH:D009362', 'Disease') :: ['metastasis']

answer: @entity14 :: (MESH:D015179,Disease) :: ['colorectal tumor']


abstract: INTRODUCTION: In Ghana, @entity311 continues to top outpatient morbidities; accounting for about 40% of all attendances. Effective case-management is key to its control. We evaluated case-management practices of uncomplicated @entity311 in Kwahu South District (KSD) health facilities to determine their conformity to guidelines. METHODS: We conducted a cross sectional survey at all public health facilities in three randomly selected sub-districts in KSD. A non-participatory observation of suspected @entity311 consultations was conducted. Suspected @entity311 was defined as any @entity1 with @entity221 (by history or measured axillary temperature > or equal 37.5 oC) presenting at the selected health facilities between 19th and 29th April 2013. Findings were expressed as frequencies, relative frequencies, mean (   standard deviation) and median. RESULTS: Of 70 clinical observations involving 10 prescribers in six health facilities, 40 (57.1%) were females and 16 (22.9%) were below five years. Median age was 18 years (interquartile range: 5-33). Overall, 63 (90.0%) suspected case- @entity1 had diagnostic tests. Two (3.6%) were treated presumptively. All 31 confirmed and 10 (33.3%) of the test negative case- @entity1 received @entity507 -based Combination Therapies (ACTs). However, only 12 (27.9%) of the 43 case- @entity1 treated with ACT received @entity506 - @entity16944 (AA). Only three (18.8%) of the under-fives were examined for non-malarial causes of @entity221 . Mean number of drugs per @entity1 was 3.7 drugs (   1.1). Only 45 (64.3%) @entity1 received at least one counseling message. CONCLUSION: Conformity of @entity311 case-management practices to guidelines in KSD was suboptimal. Apart from high rate of diagnostic testing and ACT use, prescription of AA, physical examination and counseling needed improvement.

title: Direct observation of outpatient management of XXXX in a rural ghanaian district.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'patient', 'person']

entities_list: @entity16944 :: ('MESH:D000655', 'Chemical') :: ['Amodiaquine']

entities_list: @entity507 :: ('MESH:C031327', 'Chemical') :: ['Artemisinin']

entities_list: @entity506 :: ('MESH:C039726', 'Chemical') :: ['Artesunate']

answer: @entity311 :: (MESH:D008288,Disease) :: ['malaria']


abstract: OBJECTIVES: We sought to characterise the demographics, length of admission, final diagnoses, long-term outcome and costs associated with the population who presented to an Australian @entity341 ( @entity341 ) with symptoms of possible @entity1187 ( @entity1187 ). DESIGN, SETTING AND @entity1 : Prospectively collected data on @entity341 @entity1 presenting with suspected @entity1187 between November 2008 and February 2011 was used, including data on presentation and at 30 days after presentation. Information on @entity1 disposition, length of stay and costs incurred was extracted from hospital administration records. MAIN OUTCOME MEASURES: Primary outcomes were mean and median cost and length of hospital stay. Secondary outcomes were diagnosis of @entity1187 , other @entity65 or non- @entity65 within 30 days of presentation. RESULTS: An @entity1187 was diagnosed in 103 (11.1%) of the 926 @entity1 recruited. 193 @entity1 (20.8%) were diagnosed with other cardiovascular-related conditions and 622 @entity1 (67.2%) had non-cardiac-related @entity662 . @entity1187 events occurred in 0 and 11 (1.9%) of the low-risk and intermediate-risk groups, respectively. Ninety-two (28.0%) of the 329 high-risk @entity1 had an @entity1187 event. @entity1 with a proven @entity1187 , high-grade @entity713 , @entity1151 and other respiratory conditions had the longest length of stay. The mean cost was highest in the @entity1187 group ( 13  509; 95% CI,  11  794- 15  223) followed by other @entity65 ( 7283; 95% CI,  6152- 8415) and non- @entity65 ( 3331; 95% CI,  2976- 3685). CONCLUSIONS: Most @entity341 @entity1 with symptoms of possible @entity1187 do not have a cardiac cause for their presentation. The current guideline-based process of assessment is lengthy, costly and consumes significant resources. Investigation of strategies to shorten this process or reduce the need for objective cardiac testing in @entity1 at intermediate risk according to the National Heart Foundation and Cardiac Society of Australia and New Zealand guideline is required.

title: Cost and outcomes of assessing @entity1 with @entity662 in an Australian XXXX .

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'Patients', 'patient', 'PARTICIPANTS']

entities_list: @entity1187 :: ('MESH:D054058', 'Disease') :: ['ACS', 'acute coronary syndrome']

entities_list: @entity662 :: ('MESH:D002637', 'Disease') :: ['chest pain']

entities_list: @entity713 :: ('MESH:D054537', 'Disease') :: ['atrioventricular block']

entities_list: @entity341 :: ('MESH:D004630', 'Disease') :: ['emergency department', 'ED']

entities_list: @entity1151 :: ('MESH:D011655', 'Disease') :: ['pulmonary embolism']

entities_list: @entity65 :: ('MESH:D002318', 'Disease') :: ['cardiovascular conditions']

answer: @entity341 :: (MESH:D004630,Disease) :: ['emergency department']


abstract: OBJECTIVES: We sought to characterise the demographics, length of admission, final diagnoses, long-term outcome and costs associated with the population who presented to an Australian @entity341 ( @entity341 ) with symptoms of possible @entity1187 ( @entity1187 ). DESIGN, SETTING AND @entity1 : Prospectively collected data on @entity341 @entity1 presenting with suspected @entity1187 between November 2008 and February 2011 was used, including data on presentation and at 30 days after presentation. Information on @entity1 disposition, length of stay and costs incurred was extracted from hospital administration records. MAIN OUTCOME MEASURES: Primary outcomes were mean and median cost and length of hospital stay. Secondary outcomes were diagnosis of @entity1187 , other @entity65 or non- @entity65 within 30 days of presentation. RESULTS: An @entity1187 was diagnosed in 103 (11.1%) of the 926 @entity1 recruited. 193 @entity1 (20.8%) were diagnosed with other cardiovascular-related conditions and 622 @entity1 (67.2%) had non-cardiac-related @entity662 . @entity1187 events occurred in 0 and 11 (1.9%) of the low-risk and intermediate-risk groups, respectively. Ninety-two (28.0%) of the 329 high-risk @entity1 had an @entity1187 event. @entity1 with a proven @entity1187 , high-grade @entity713 , @entity1151 and other respiratory conditions had the longest length of stay. The mean cost was highest in the @entity1187 group ( 13  509; 95% CI,  11  794- 15  223) followed by other @entity65 ( 7283; 95% CI,  6152- 8415) and non- @entity65 ( 3331; 95% CI,  2976- 3685). CONCLUSIONS: Most @entity341 @entity1 with symptoms of possible @entity1187 do not have a cardiac cause for their presentation. The current guideline-based process of assessment is lengthy, costly and consumes significant resources. Investigation of strategies to shorten this process or reduce the need for objective cardiac testing in @entity1 at intermediate risk according to the National Heart Foundation and Cardiac Society of Australia and New Zealand guideline is required.

title: Cost and outcomes of assessing @entity1 with XXXX in an Australian @entity341 .

answer: @entity662 :: (MESH:D002637,Disease) :: ['chest pain']


abstract: OBJECTIVES: We sought to characterise the demographics, length of admission, final diagnoses, long-term outcome and costs associated with the population who presented to an Australian @entity341 ( @entity341 ) with symptoms of possible @entity1187 ( @entity1187 ). DESIGN, SETTING AND @entity1 : Prospectively collected data on @entity341 @entity1 presenting with suspected @entity1187 between November 2008 and February 2011 was used, including data on presentation and at 30 days after presentation. Information on @entity1 disposition, length of stay and costs incurred was extracted from hospital administration records. MAIN OUTCOME MEASURES: Primary outcomes were mean and median cost and length of hospital stay. Secondary outcomes were diagnosis of @entity1187 , other @entity65 or non- @entity65 within 30 days of presentation. RESULTS: An @entity1187 was diagnosed in 103 (11.1%) of the 926 @entity1 recruited. 193 @entity1 (20.8%) were diagnosed with other cardiovascular-related conditions and 622 @entity1 (67.2%) had non-cardiac-related @entity662 . @entity1187 events occurred in 0 and 11 (1.9%) of the low-risk and intermediate-risk groups, respectively. Ninety-two (28.0%) of the 329 high-risk @entity1 had an @entity1187 event. @entity1 with a proven @entity1187 , high-grade @entity713 , @entity1151 and other respiratory conditions had the longest length of stay. The mean cost was highest in the @entity1187 group ( 13  509; 95% CI,  11  794- 15  223) followed by other @entity65 ( 7283; 95% CI,  6152- 8415) and non- @entity65 ( 3331; 95% CI,  2976- 3685). CONCLUSIONS: Most @entity341 @entity1 with symptoms of possible @entity1187 do not have a cardiac cause for their presentation. The current guideline-based process of assessment is lengthy, costly and consumes significant resources. Investigation of strategies to shorten this process or reduce the need for objective cardiac testing in @entity1 at intermediate risk according to the National Heart Foundation and Cardiac Society of Australia and New Zealand guideline is required.

title: Cost and outcomes of assessing XXXX with @entity662 in an Australian @entity341 .

answer: @entity1 :: (9606,Species) :: ['patients']


abstract: UNASSIGNED: Chlamydia is a common sexually transmitted infection that has potentially serious consequences unless detected and treated early. The health service in the UK offers clinic-based testing for @entity1047 but uptake is low. Identifying the predictors of testing behaviours may inform interventions to increase uptake. Self-tests for @entity1047 may facilitate testing and treatment in @entity1 who avoid clinic-based testing. Self-testing and being tested by a @entity283 ( @entity283 ) involve two contrasting contexts that may influence testing behaviour. However, little is known about how predictors of behaviour differ as a function of context. In this study, theoretical models of behaviour were used to assess factors that may predict intention to test in two different contexts: self-testing and being tested by a @entity283 . Individuals searching for or reading about @entity1047 testing online were recruited using Google Adwords. @entity1 completed an online questionnaire that addressed previous testing behaviour and measured constructs of the Theory of Planned Behaviour and Protection Motivation Theory, which propose a total of eight possible predictors of intention. The questionnaire was completed by 310 @entity1 . Sufficient data for multiple regression were provided by 102 and 118 respondents for self-testing and testing by a @entity283 respectively. Intention to self-test was predicted by vulnerability and self-efficacy, with a trend-level effect for response efficacy. Intention to be tested by a @entity283 was predicted by vulnerability, attitude and subjective norm. Thus, intentions to carry out two testing behaviours with very similar goals can have different predictors depending on test context. We conclude that interventions to increase self-testing should be based on evidence specifically related to test context.

title: An online study combining the constructs from the theory of planned behaviour and protection motivation theory in predicting intention to test for XXXX in two testing contexts.

entities_list: @entity1 :: ('9606', 'Species') :: ['participants', 'Participants', 'people']

entities_list: @entity1047 :: ('MESH:D002690', 'Disease') :: ['chlamydia']

entities_list: @entity283 :: ('OMIM:603663', 'Disease') :: ['health care professional', 'HCP']

answer: @entity1047 :: (MESH:D002690,Disease) :: ['chlamydia']


abstract: PURPOSE: Much attention has been paid to preoperative treatment as a new strategy especially for borderline resectable @entity788 (BRPC). The purpose of this study was to define the optimal indication of neoadjuvant chemoradiotherapy (NACRT) for @entity788 . METHODS: We analyzed consecutive 184 @entity1 who had undergone pancreatic resection in Nara Medical University Hospital. Resectability status was classified by NCCN guidelines. Full-dose @entity136 with concurrent radiation was used as NACRT. We evaluated 85 @entity1 treated with NACRT in comparison with 99 @entity1 without NACRT as control. RESULTS: The regimen of NACRT was well tolerated and feasible. The perioperative outcomes were almost comparable. The postoperative complications were significantly less frequent in NACRT group than non-NACRT group. The pathological effects on both resectable and borderline @entity5 were favorable in NACRT group compared to non-NACRT group. The overall survival of resectable @entity788 was significantly better than that of BRPC regardless of whether the @entity1 were treated with or without NACRT. The prognosis of the @entity1 with NACRT in resectable @entity5 was significantly better than without, while there was no significant difference in BRPC. Furthermore, multivariate analysis of various factors in the @entity1 with NACRT identified resectability status and completion of adjuvant chemotherapy as independent prognostic factors. CONCLUSIONS: NACRT did not improve the prognosis of the @entity1 with BRPC, although it induced substantial pathological antitumor effect. In contrast, the prognosis of resectable @entity788 treated with NACRT was favorable. Therefore, resectable @entity788 may be good indication for multimodal treatment including NACRT.

title: Optimal indication of neoadjuvant chemoradiotherapy for XXXX .

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity788 :: ('MESH:D010190', 'Disease') :: ['pancreatic cancer']

entities_list: @entity136 :: ('MESH:C056507', 'Chemical') :: ['gemcitabine']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['tumors']

answer: @entity788 :: (MESH:D010190,Disease) :: ['pancreatic cancer']


abstract: OBJECT The authors' aim was perform a systematic review on the incidence of @entity428 ( @entity428 ) after surgery for @entity91 . METHODS A systematic literature review was conducted using PubMed to assess the rate of @entity428 in studies published between 1985 and 2014. Inclusion criteria were 1) English-language literature; 2) @entity1 subjects; 3) pediatric cases; and 4) @entity428 confirmed with invasive intracranial pressure monitoring. RESULTS Seven studies met inclusion criteria. @entity428 was reported to be present in 5% of @entity1 postoperatively with @entity91 and 4% of @entity1 with all forms of @entity91 . Inadequate numbers were available to determine the incidence of @entity428 for syndromic and individual nonsyndromic sutural synostosis based on the inclusion criteria. Surgical groups were subdivided into cranial remodeling procedures without orbital advancement and craniofacial procedures with orbital advancement. @entity428 was reported to be present in 5% of @entity1 with all forms of @entity850 after cranial remodeling procedures and 1% after craniofacial advancement. CONCLUSIONS Postoperative development of @entity428 has been described by multiple institutions, but the variation in how @entity428 is determined and the multiple surgical procedures to correct @entity91 has limited the number of studies subject to a meta-analysis. Nonetheless, this entity deserves special attention, and further studies are required to determine the true incidence of @entity428 , including the role of various surgical procedures on its incidence. The long-term consequences of chronic @entity428 in this group of @entity1 also need to be evaluated.

title: Intracranial hypertension after surgical correction for XXXX : a systematic review.

entities_list: @entity91 :: ('MESH:D003398', 'Disease') :: ['sagittal synostosis', 'craniosynostosis', 'nonsyndromic craniosynostosis']

entities_list: @entity1 :: ('9606', 'Species') :: ['human', 'patients']

entities_list: @entity850 :: ('MESH:D003251', 'Disease') :: ['nonsyndromic sutural stenosis']

entities_list: @entity428 :: ('MESH:D019586', 'Disease') :: ['postoperative IH', 'elevated intracranial pressure', 'intracranial hypertension', 'IH']

answer: @entity91 :: (MESH:D003398,Disease) :: ['craniosynostosis']


abstract: BACKGROUND: In our exploratory studies, we associated single nucleotide polymorphisms (SNPs) in candidate genes with the efficacy and @entity137 of sunitinib in @entity1358 ( @entity1358 ). OBJECTIVE: To see whether previously reported associations of SNPs with sunitinib-induced @entity137 and efficacy in @entity1358 can be confirmed in a large cohort of @entity1 . DESIGN, SETTING, AND @entity1 : The @entity1358 @entity1 treated with sunitinib and a DNA sample available were pooled from three exploratory studies conducted in the United States, Spain, and the Netherlands. A total of 22 SNPs and 6 haplotypes in 10 candidate genes related to the pharmacokinetics and pharmacodynamics of sunitinib were selected for association testing. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: SNPs and haplotypes were tested for associations with @entity137 , dose reductions, progression-free survival (PFS), overall survival (OS), and best objective response. RESULTS AND LIMITATIONS: A total of 333 @entity1 were included. We confirmed 2 of the 22 previously reported SNP associations. The presence of @entity5396 *1 was associated with dose reductions (odds ratio: 2.0; 95% confidence interval [CI], 1.0-4.0, p=0.039). The presence of @entity49139 in the @entity1262 haplotype was associated with an increased PFS (hazard ratio: 1.9; 95% CI, 1.3-2.6; p<0.001) and remained significant after Bonferroni correction. These associations are consistent with prior observations. CONCLUSIONS: The confirmation of previously reported associations between polymorphisms in @entity5396 and @entity1262 with sunitinib @entity137 and efficacy, respectively, indicates that genotyping of these genetic variants will be useful for guiding sunitinib treatment. A prospective validation study is needed to confirm our findings on @entity1262 and @entity5396 genetic polymorphisms. @entity1 SUMMARY: We confirmed that variants in genes involved in processing sunitinib through the body have an effect on sunitinib treatment outcome. These findings confirm the potential of testing for these genetic variants to improve individual @entity1 care for @entity1 with @entity1358 treated with sunitinib.

title: @entity5396 and @entity1262 polymorphisms as predictors for sunitinib outcome in XXXX .

entities_list: @entity1 :: ('9606', 'Species') :: ['PATIENT', 'patients', 'patient', 'PARTICIPANTS']

entities_list: @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicity', 'toxicities']

entities_list: @entity1358 :: ('MESH:D002292', 'Disease') :: ['mRCC', 'metastatic renal cell carcinoma']

answer: @entity1358 :: (MESH:D002292,Disease) :: ['metastatic renal cell carcinoma']


abstract: BACKGROUND: In our exploratory studies, we associated single nucleotide polymorphisms (SNPs) in candidate genes with the efficacy and @entity137 of sunitinib in @entity1358 ( @entity1358 ). OBJECTIVE: To see whether previously reported associations of SNPs with sunitinib-induced @entity137 and efficacy in @entity1358 can be confirmed in a large cohort of @entity1 . DESIGN, SETTING, AND @entity1 : The @entity1358 @entity1 treated with sunitinib and a DNA sample available were pooled from three exploratory studies conducted in the United States, Spain, and the Netherlands. A total of 22 SNPs and 6 haplotypes in 10 candidate genes related to the pharmacokinetics and pharmacodynamics of sunitinib were selected for association testing. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: SNPs and haplotypes were tested for associations with @entity137 , dose reductions, progression-free survival (PFS), overall survival (OS), and best objective response. RESULTS AND LIMITATIONS: A total of 333 @entity1 were included. We confirmed 2 of the 22 previously reported SNP associations. The presence of @entity5396 *1 was associated with dose reductions (odds ratio: 2.0; 95% confidence interval [CI], 1.0-4.0, p=0.039). The presence of @entity49139 in the @entity1262 haplotype was associated with an increased PFS (hazard ratio: 1.9; 95% CI, 1.3-2.6; p<0.001) and remained significant after Bonferroni correction. These associations are consistent with prior observations. CONCLUSIONS: The confirmation of previously reported associations between polymorphisms in @entity5396 and @entity1262 with sunitinib @entity137 and efficacy, respectively, indicates that genotyping of these genetic variants will be useful for guiding sunitinib treatment. A prospective validation study is needed to confirm our findings on @entity1262 and @entity5396 genetic polymorphisms. @entity1 SUMMARY: We confirmed that variants in genes involved in processing sunitinib through the body have an effect on sunitinib treatment outcome. These findings confirm the potential of testing for these genetic variants to improve individual @entity1 care for @entity1 with @entity1358 treated with sunitinib.

title: XXXX and @entity1262 polymorphisms as predictors for sunitinib outcome in @entity1358 .

answer: @entity5396 :: (1577,Gene) :: ['CYP3A5']


abstract: BACKGROUND: In our exploratory studies, we associated single nucleotide polymorphisms (SNPs) in candidate genes with the efficacy and @entity137 of sunitinib in @entity1358 ( @entity1358 ). OBJECTIVE: To see whether previously reported associations of SNPs with sunitinib-induced @entity137 and efficacy in @entity1358 can be confirmed in a large cohort of @entity1 . DESIGN, SETTING, AND @entity1 : The @entity1358 @entity1 treated with sunitinib and a DNA sample available were pooled from three exploratory studies conducted in the United States, Spain, and the Netherlands. A total of 22 SNPs and 6 haplotypes in 10 candidate genes related to the pharmacokinetics and pharmacodynamics of sunitinib were selected for association testing. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: SNPs and haplotypes were tested for associations with @entity137 , dose reductions, progression-free survival (PFS), overall survival (OS), and best objective response. RESULTS AND LIMITATIONS: A total of 333 @entity1 were included. We confirmed 2 of the 22 previously reported SNP associations. The presence of @entity5396 *1 was associated with dose reductions (odds ratio: 2.0; 95% confidence interval [CI], 1.0-4.0, p=0.039). The presence of @entity49139 in the @entity1262 haplotype was associated with an increased PFS (hazard ratio: 1.9; 95% CI, 1.3-2.6; p<0.001) and remained significant after Bonferroni correction. These associations are consistent with prior observations. CONCLUSIONS: The confirmation of previously reported associations between polymorphisms in @entity5396 and @entity1262 with sunitinib @entity137 and efficacy, respectively, indicates that genotyping of these genetic variants will be useful for guiding sunitinib treatment. A prospective validation study is needed to confirm our findings on @entity1262 and @entity5396 genetic polymorphisms. @entity1 SUMMARY: We confirmed that variants in genes involved in processing sunitinib through the body have an effect on sunitinib treatment outcome. These findings confirm the potential of testing for these genetic variants to improve individual @entity1 care for @entity1 with @entity1358 treated with sunitinib.

title: @entity5396 and XXXX polymorphisms as predictors for sunitinib outcome in @entity1358 .

answer: @entity1262 :: (5243,Gene) :: ['ABCB1']


abstract: UNASSIGNED: The direct analysis in real time (DART) ionization source coupled with quadrupole time-of-flight tandem mass spectrometry (Q-TOF @entity15 / @entity15 ) system has the capability to desorb analytes directly from samples without sample cleanup or chromatographic separation. In this work, a method based on DART/Q-TOF @entity15 / @entity15 has been developed for rapid identification of @entity31769 ( @entity6061 ) present in powdered milk. Simple sample extraction procedure employing @entity1626 -water (80:20, v/v) mixture was followed by direct, high-throughput determination of sample extracts spread on a steel mesh of the transmission module by mass spectrometry under ambient conditions. The method has been evaluated for both qualitative and quantitative analysis of @entity6061 in powdered milk. Variables including experimental apparatus, DART gas heater temperature, sample presentation speed, and vacuum pressure were investigated. The quantitative method was validated with respect to linearity, sensitivity, repeatability, precision, and accuracy by using external standards. After optimization of these parameters, a limit of detection (LOD) of 100  g kg(-1) was obtained for @entity6061 with a linear working range from 100 to 10000  g kg(-1) and a satisfactory correlation coefficient (R(2)) of 0.9997. Good recovery (80.08%-106.47%) and repeatability (RSD   =   3.0%-5.4%) were achieved for @entity6061 . The DART/Q-TOF @entity15 / @entity15 -based method provides a rapid, efficient, and powerful scheme to analyze @entity6061 in powdered milk with limited sample preparation, thus reducing time and complexity of quality control. Graphical Abstract    .

title: Determination of XXXX in Powdered Milk Using Direct Analysis in Real Time Quadrupole Time-of-Flight Tandem Mass Spectrometry.

entities_list: @entity1626 :: ('MESH:C032159', 'Chemical') :: ['acetonitrile']

entities_list: @entity31769 :: ('MESH:C004711', 'Chemical') :: ['dicyandiamide']

answer: @entity31769 :: (MESH:C004711,Chemical) :: ['Dicyandiamide']


abstract: INTRODUCTION: Endometriosis affects approximately 10-15% of reproductive-aged @entity1 . The disease is characterized by functional endometrial glands outside the uterine cavity; peritoneal, ovarian, and deep infiltrating @entity75 can be distinguished. Epithelial-mesenchymal transition describes the conversion of stationary epithelial cells into proliferative and invasive mesenchymal cells. The canonical Wnt-signaling system serves as an important driver for epithelial-mesenchymal transition. Hence, it was the study objective to quantify the expression changes of 1) Wnt-signaling pathway genes and 2) Wnt-target genes-also playing a role in epithelial-mesenchymal transition-in @entity46 tissues. METHODS: Real-time polymerase chain reaction was applied to 77 tissue samples collected from reproductive-aged @entity1 with and without @entity46 in different stages of their cycles. RESULTS: In the endometria of those in the case and control groups, expression of Wnt agonists was significantly increased in the luteal compared with the follicular phase of the cycle. Levels of Wnt-signaling receptors were down-regulated in the endometria of @entity46 @entity1 compared with those in the control group. In @entity43 , the expression of Wnt-signaling agonists, antagonists, and receptors as well as Wnt-target genes relevant in epithelial-mesenchymal transition was significantly altered when compared with matching endometrial samples. CONCLUSION: The expression of endometrial Wnt-signaling genes varies in different phases of the cycle; the expression pattern differs between those with and without @entity46 . Expression of genes encoding for the Wnt-signaling system as well as Wnt-target genes involved in epithelial-mesenchymal transition is regulated differently in @entity46 and endometrium. Therefore, we hypothesize that altered Wnt-signaling may result in epithelial-mesenchymal transition of @entity46 cells, serving as prerequisite for the establishment and maintenance of ectopic lesions.

title: Expression of Wnt-Signaling Pathway Genes and Wnt-Target Genes in XXXX Endometriosis Tissue [25].

entities_list: @entity1 :: ('9606', 'Species') :: ['women', 'patients']

entities_list: @entity46 :: ('MESH:D004715', 'Disease') :: ['endometriosis']

entities_list: @entity75 :: ('MESH:D001927', 'Disease') :: ['endometriosis lesions']

entities_list: @entity43 :: ('MESH:D010051', 'Disease') :: ['ovarian endometriosis']

answer: @entity1 :: (9606,Species) :: ['Human']


abstract: OBJECTIVE: To assess the efficacy and @entity137 profile of dose-dense @entity900 -based neoadjuvant chemotherapy (NACT) followed by radical surgery in @entity1 affected by locally advanced @entity5 . METHODS: @entity1 affected by @entity2622 FIGO (International Federation of Obstetrics and Gynecology) stage @entity3847 were enrolled into the study. The treatment schedule consisted of 5 cycles of intravenous @entity1311 60 mg/m(2) plus @entity900 60 mg/m(2) every 10 days; @entity1 were then submitted to radical hysterectomy and pelvic lymphadenectomy. RESULTS: From January 2011 to March 2013, 22 @entity1 were enrolled. Median age was 47 (26-83) years. FIGO stages included 1 IIA, 15 IIB, 1 IIIA, and 5 IIIB. Ninety-one percent of @entity1 completed all the 5 planned cycles of NACT. Three @entity1 experienced @entity56 to @entity1311 . Grade 3-4 hematological @entity137 was observed in 18% of cases. In 3 cases, grade 3-4 extra-hematological adverse and life-threatening events were reported (1 @entity2167 , 1 transient @entity63 attack, and 1 @entity583 ). No treatment-related @entity204 occurred. The operability rate was 86.4%. The overall response rate was 52.6%: 5 @entity1 (26.3%) experienced clinical complete response, and 5 (26.3%) showed a clinical partial response. Stable disease was observed in 47.4% of @entity1 , with no progressive disease recorded. Pathological response was observed in 57.9% of cases. Six out of 19 (31.6%) @entity1 were submitted to adjuvant treatment. CONCLUSION: Dose-dense @entity900 -based NACT showed a response rate in approximately half of @entity1 . However, in consideration of the reported extra-hematological @entity137 , further studies on and new strategies with dose-dense @entity902 -based NACT are required to improve outcome in @entity5 @entity1 .    2015 S. Karger AG, Basel.

title: Dose-Dense Neoadjuvant Chemotherapy plus Radical Surgery in Locally Advanced XXXX : A Phase II Study.

entities_list: @entity1 :: ('9606', 'Species') :: ['Patients', 'patients']

entities_list: @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicity']

entities_list: @entity2167 :: ('MESH:D006311', 'Disease') :: ['ototoxicity']

entities_list: @entity63 :: ('MESH:D007511', 'Disease') :: ['ischemic']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['cervical cancer']

entities_list: @entity900 :: ('MESH:D002945', 'Chemical') :: ['cisplatin']

entities_list: @entity2622 :: ('MESH:D002583', 'Disease') :: ['carcinoma of the uterine cervix']

entities_list: @entity1311 :: ('MESH:D017239', 'Chemical') :: ['paclitaxel']

entities_list: @entity56 :: ('MESH:D004342', 'Disease') :: ['allergic reactions']

entities_list: @entity583 :: ('MESH:D009203', 'Disease') :: ['myocardial infarction']

entities_list: @entity902 :: ('MESH:D010984', 'Chemical') :: ['platinum']

answer: @entity5 :: (MESH:D009369,Disease) :: ['Cervical Cancer']


abstract: BACKGROUND: Effective surveillance and estimation of the biting fraction of @entity4224 is critical for accurate determination of the extent of virus transmission during outbreaks and inter-epidemic periods of dengue and @entity12517 . Here, we describe the development and use of synthetic @entity1 odor baits for improved sampling of adult Ae. aegypti, in two dengue and @entity12517 fevers endemic areas in Kenya; Kilifi and Busia counties. METHODS: We collected volatiles from the feet and trunks of two female and two male volunteers aged between 25 and 45  years. We used coupled gas chromatography- electroantennographic detection (GC/EAD) analysis to screen for antennally-active components from the volatiles and coupled GC-mass spectrometry (GC/MS) to identify the EAD-active components. Using randomized replicated designs, we compared the efficacies of Biogents (BG) sentinel traps baited with @entity544 plus either single or blends of the identified compounds against the BG sentinel trap baited with @entity544 plus the BG commercial lure in trapping Ae. aegypti. The daily mosquito counts in the different traps were subjected to negative binomial regression following the generalized linear models procedures. RESULTS: A total of ten major EAD-active components identified by GC/MS as mainly @entity3125 and @entity7574 , were consistently isolated from the @entity1 feet and trunk volatiles from at least two volunteers. Field assays with synthetic chemicals of the shared EAD-active components identified from the feet and trunk gave varying results. Ae. aegypti were more attracted to @entity544 baited BG sentinel traps combined with blends of @entity3125 than to similar traps combined with blends of @entity7574 . When we assessed the efficacy of @entity35799 detected in odors of the BG commercial lure and volunteers plus @entity544 , trap captures of Ae. aegypti doubled over the trap baited with the commercial BG lure. However, dispensing @entity3125 and @entity7574 together in blends, reduced trap captures of Ae. aegypti by ~45%-50%. CONCLUSIONS: Our results provide evidence for roles of @entity7574 and @entity3125 in Ae. aegypti host attraction and also show that of the @entity7574 , @entity35799 is a more effective lure for the vector than the BG commercial lure.

title: An improved odor bait for monitoring populations of XXXX -vectors of dengue and chikungunya viruses in Kenya.

entities_list: @entity12517 :: ('MESH:D065632', 'Disease') :: ['chikungunya fever', 'chikungunya']

entities_list: @entity4224 :: ('7159', 'Species') :: ['Aedes aegypti']

entities_list: @entity7574 :: ('MESH:D002264', 'Chemical') :: ['carboxylic acids']

entities_list: @entity35799 :: ('MESH:C037652', 'Chemical') :: ['hexanoic acid']

entities_list: @entity3125 :: ('MESH:D000447', 'Chemical') :: ['aldehydes']

entities_list: @entity544 :: ('MESH:D002245', 'Chemical') :: ['carbon dioxide']

answer: @entity4224 :: (7159,Species) :: ['Aedes aegypti']


abstract: INTRODUCTION: To characterize etiology, clinical course and outcomes of @entity1 in @entity159 ( @entity159 ) and looking for prognostic factors. METHODS: Retrospective study conducted in @entity1 hospitalized from January 1, 2001 to December 31, 2011 in 19 polyvalent intensive care units in French university and general hospitals. @entity1 were adults with a generalized @entity410 @entity159 that lasted more than seven days, despite treatment including an anesthetic drug and mechanical ventilation. @entity1 with @entity75 were excluded. Follow-up phone call was used to determine functional outcome using modified Rankin Scale (mRS) with mRS 0-3 defining good and mRS 4-6 poor outcome. RESULTS: 78 @entity1 (35 female) were included. Median age was 57 years. Causes of @entity159 were various, mainly including prior @entity302 (14.1%), CNS @entity281 (12.8%), and @entity64 (12.8%). No etiology was found in 27 (34.6%) @entity1 . @entity159 was considered controlled in only 53 (67.9%) @entity1 after a median duration of 17 (IQR 12-26) days. The median length of ICU stay was 28 (19-48) days. Forty-one (52.5%) @entity1 died in the ICU, 26 from @entity881 , 8 from care withdrawal, 2 from @entity1164 , 1 from @entity1620 and 4 from unknown causes. @entity159 was previously resolved in 20 @entity1 who died in the ICU. At one-year follow-up, there were 12 @entity1 with good outcome and 58 with poor outcome and 8 lost of follow-up. On multivariate analysis, only vasopressor use was a predictor of poor outcome (OR 6.54; 95%CI 1.09-39.29; p = 0.04). CONCLUSION: Poor outcome was observed in about 80% of this population of @entity159 . Most @entity1 died from systemic complications linked to their ICU stay. Some @entity1 can recover satisfactorily over time though we did not identify any robust factor of good outcome.

title: Functional outcome of XXXX .

entities_list: @entity1 :: ('9606', 'Species') :: ['Patients', 'patients']

entities_list: @entity1164 :: ('MESH:D016757', 'Disease') :: ['sudden cardiac arrest']

entities_list: @entity410 :: ('MESH:D012640', 'Disease') :: ['convulsive']

entities_list: @entity75 :: ('MESH:D001927', 'Disease') :: ['anoxic encephalopathy']

entities_list: @entity281 :: ('MESH:D007239', 'Disease') :: ['infection']

entities_list: @entity1620 :: ('MESH:D001926', 'Disease') :: ['brain death']

entities_list: @entity302 :: ('MESH:D004827', 'Disease') :: ['epilepsy']

entities_list: @entity881 :: ('MESH:D009102', 'Disease') :: ['multiple organ failure']

entities_list: @entity159 :: ('MESH:D013226', 'Disease') :: ['status epilepticus', 'refractory status epilepticus', 'PRSE', 'prolonged refractory status epilepticus']

answer: @entity159 :: (MESH:D013226,Disease) :: ['prolonged refractory status epilepticus']


abstract: @entity10133 (FVII) deficiency is a rare @entity3459 caused by mutations in the F7 gene. The aims of this study were to characterize the molecular defect of F7 in Korean @entity1 with @entity5630 and to find genotype-phenotype correlations. Study individuals consisted of 14 unrelated Korean @entity1 with @entity5630 with residual FVII activities ranging from 1 to 34%. To identify causative mutations, we performed PCR amplification and direct sequencing of all exons and flanking sequences of F7 gene. In all 14 @entity1 , one (N = 4) or two (N = 10) mutant alleles were identified. A total of 11 unique mutations were detected, of which four were novel ( @entity72052 , @entity72053 , @entity72054 , and @entity72055 ). Four recurrent mutations were observed in 86% of @entity1 (12 of 14) ( @entity72056 , @entity72057 , @entity72058 , and @entity55247 ) and accounted for 71% of all mutant alleles (17 of 24). The residual FVII activity was more than 5% in all six asymptomatic @entity1 (21%, range 6-34%), whereas it was 5% or less in all eight symptomatic @entity1 (2%, range 1-5%). In addition, the mean residual FVII activity in four @entity1 with a single mutant allele was 23.6% (range 3-34%), which was significantly higher than that in 10 @entity1 with two mutant alleles that was 4.6% (range 1-19%) (P = 0.023). In summary, the data from this study on the largest number of @entity5630 in Korea showed recurrent mutations in this population and suggested genotype-phenotype correlations.

title: Recurrent mutations and genotype-phenotype correlations in XXXX in Korea.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity5630 :: ('MESH:D005168', 'Disease') :: ['FVII deficiency']

entities_list: @entity3459 :: ('MESH:D025861', 'Disease') :: ['hereditary coagulopathy']

entities_list: @entity10133 :: ('2155', 'Gene') :: ['Coagulation factor VII']

entities_list: @entity72054 :: ('p|DUP|60|R,RR', 'ProteinMutation') :: ['p.R59_R60dupRR']

answer: @entity5630 :: (MESH:D005168,Disease) :: ['hereditary factor VII deficiency']


abstract: AIM: To evaluate the efficacy of radiation therapy for para-aortic lymph node @entity3 from @entity5 and to identify an optimal radiation regimen. @entity1 AND METHODS: A total of 80 metastatic para-aortic lymph nodes, ranging from 11-50 mm (median=20 mm) on computed tomography, in 22 @entity1 with @entity957 were initially treated with radiation therapy. Total radiation doses for para-aortic lymph node @entity3 were 40-61.2 Gy (median=50.4 Gy) in 1.8-2 Gy fractions. RESULTS: Eight out of the 22 @entity1 remained alive at a median follow-up of 32 months. Seven irradiated lymph nodes, 20-50 mm in diameter, in four @entity1 progressed after irradiation at total doses of 44-50.4 Gy. No metastatic lymph nodes administered >50.4 Gy (median=55.8 Gy) exhibited progression after irradiation. All metastatic lymph nodes  <=25 mm in diameter irradiated with 50 or 50.4 Gy were controlled. The 3-year lymph node progression-free rates were 78% in the cohort of 22 @entity1 and 89% considering all 80 metastatic lymph nodes. Apart from transient hematological reactions, two @entity1 developed grade 3 or more therapy-related @entity137 , including @entity1161 in one and @entity2335 and @entity1960 in another. CONCLUSION: Radiation therapy can effectively control para-aortic lymph node @entity3 in @entity1 with @entity5 . A total dose of 50.4 Gy in 1.8 Gy fractions is sufficient to control metastatic lymph nodes  <=25 mm in diameter, whereas a higher dose (approximately 55.8 Gy) may be required for larger nodes.

title: Radiation Therapy for Para-Aortic Lymph Node XXXX from Uterine Cervical @entity5 .

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'PATIENTS']

entities_list: @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicities']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['uterine cervical cancer']

entities_list: @entity1161 :: ('MESH:D011832', 'Disease') :: ['radiation proctitis']

entities_list: @entity957 :: ('MESH:D002294', 'Disease') :: ['squamous cell carcinoma of the uterine cervix']

entities_list: @entity3 :: ('MESH:D009362', 'Disease') :: ['metastases']

entities_list: @entity2335 :: ('MESH:D003556', 'Disease') :: ['hemorrhagic cystitis']

answer: @entity3 :: (MESH:D009362,Disease) :: ['Metastasis']


abstract: AIM: To evaluate the efficacy of radiation therapy for para-aortic lymph node @entity3 from @entity5 and to identify an optimal radiation regimen. @entity1 AND METHODS: A total of 80 metastatic para-aortic lymph nodes, ranging from 11-50 mm (median=20 mm) on computed tomography, in 22 @entity1 with @entity957 were initially treated with radiation therapy. Total radiation doses for para-aortic lymph node @entity3 were 40-61.2 Gy (median=50.4 Gy) in 1.8-2 Gy fractions. RESULTS: Eight out of the 22 @entity1 remained alive at a median follow-up of 32 months. Seven irradiated lymph nodes, 20-50 mm in diameter, in four @entity1 progressed after irradiation at total doses of 44-50.4 Gy. No metastatic lymph nodes administered >50.4 Gy (median=55.8 Gy) exhibited progression after irradiation. All metastatic lymph nodes  <=25 mm in diameter irradiated with 50 or 50.4 Gy were controlled. The 3-year lymph node progression-free rates were 78% in the cohort of 22 @entity1 and 89% considering all 80 metastatic lymph nodes. Apart from transient hematological reactions, two @entity1 developed grade 3 or more therapy-related @entity137 , including @entity1161 in one and @entity2335 and @entity1960 in another. CONCLUSION: Radiation therapy can effectively control para-aortic lymph node @entity3 in @entity1 with @entity5 . A total dose of 50.4 Gy in 1.8 Gy fractions is sufficient to control metastatic lymph nodes  <=25 mm in diameter, whereas a higher dose (approximately 55.8 Gy) may be required for larger nodes.

title: Radiation Therapy for Para-Aortic Lymph Node @entity3 from Uterine Cervical XXXX .

answer: @entity5 :: (MESH:D009369,Disease) :: ['Cancer']


abstract: Iceland has a total population of 300,000 inhabitants. All @entity1 consulting for symptoms of the lower digestive tract during a four-year period (2003-2006) were subjected to a colonoscopic examination; all @entity1127 were endoscopically removed. Out of the total 3,037 @entity2513 ( @entity2513 ), 308 (10.2%) were @entity652 ( @entity652 ). @entity652 were divided according the predominant histological phenotype (>50%) into those with ectopic crypt formations (ECF), and those with unlocked serrations (US). ECF- @entity10319 accounted for 5.9% (178/3037) and US- @entity10319 for 4.3% (130/3037). The majority of @entity1 with ECF- @entity10319 and US- @entity10319 were >= 60 years of age (74.1% and 76.2%, respectively). Notwithstanding, when @entity1 having advanced @entity652 (with high-grade @entity1141 , with or without @entity189 ) were listed by age, those with ECF- @entity10319 were significantly younger than those with US- @entity10319 (p<0.05). ECF- @entity10319 were more frequently left-sided (71.8%), whereas US- @entity10319 were more frequently right-sided (60.0%). @entity189 evolved more frequently in ECF- @entity10319 (7.8%) and in US- @entity10319 (7.7%) than in tubular @entity652 and in villous/tubulovillous adenonas (0.1% and 4.4%, respectively). Comparative studies indicated that the incidence rates/year of ECF- @entity10319 and US- @entity10319 were significantly higher in Iceland than in Sweden or in Italy (p<0.05). Genetic and putative epigenetic (environmental) factor(s) might account for the high incidence rate/year of ECF- @entity10319 and US- @entity10319 in this country.

title: Two Phenotypes of Traditional Serrated XXXX Nationwide Survey in Iceland.

entities_list: @entity189 :: ('MESH:D002277', 'Disease') :: ['intramucosal carcinoma', 'Invasive carcinoma']

entities_list: @entity652 :: ('MESH:D000236', 'Disease') :: ['adenomas', 'traditional serrated adenomas', 'TSAs']

entities_list: @entity1141 :: ('MESH:C535662', 'Disease') :: ['dysplasia']

entities_list: @entity2513 :: ('MESH:C563365', 'Disease') :: ['CRAs', 'colorectal adenomas']

answer: @entity652 :: (MESH:D000236,Disease) :: ['Adenomas']


abstract: PURPOSE: To determine the correlations and strength of association between different imaging systems in analyzing the retinal nerve fiber layer (RNFL) of @entity726 @entity1 : optical coherence tomography ( @entity6653 ), scanning laser polarimetry (SLP) and confocal scanning laser ophthalmoscopy (CSLO). MATERIALS AND METHODOLOGY: 114 eyes of @entity1 with moderate @entity1538 underwent spectral domain @entity6653 (Topcon SD- @entity6653 2000 and Zeiss Cirrus HD- @entity6653 ), SLP ( @entity9999 Pro) and CSLO (Heidelberg Retina Tomograph, @entity12447 ). Correlation coefficients were calculated between the structural parameters yielded by these examinations. The quantitative relationship between the measured RNFL thickness globally and for the four regions (superior, inferior, nasal, temporal) were evaluated with different regression models for all used imaging systems. RESULTS: The strongest correlation of RNFL measurements was found between devices using the same technology like @entity9999 VCC and @entity9999 Pro as well as Topcon @entity6653 and Cirrus @entity6653 . In @entity726 @entity1 , the strongest associations (R  ) were found between RNFL measurements of the two optical coherence tomography devices Topcon @entity6653 and Cirrus @entity6653 (R   = 0.513) and between @entity9999 VCC and @entity9999 Pro (R   = 0.451). The results of the OCTs and @entity9999 Pro also had a strong quantitative relationship (Topcon @entity6653 R   = 0.339 and Cirrus @entity6653 R   = 0.347). @entity9999 VCC and the OCTs showed a mild to moderate association (Topcon @entity6653 R   = 0.207 and Cirrus @entity6653 R   = 0.258). The confocal scanning laser ophthalmoscopy ( @entity12447 ) had the lowest association to all other devices (Topcon @entity6653 R   = 0.254, Cirrus @entity6653 R   = 0.158, @entity9999 Pro R   = 0.086 and @entity9999 VCC R   = 0.1). CONCLUSION: The measurements of the RNFL in @entity726 @entity1 reveal a high correlation of @entity6653 and @entity9999 devices because OCTs can measure all major retinal layers and SLP can detect nerve fibers allowing a comparison between the results of this devices. However, CSLO by means of HRT topography can only measure height values of the retinal surface but it cannot distinguish between different retinal layers. This may explain the rather poor correlations and associations between CSLO measurements and those of all other imaging devices which makes it difficult to compare @entity12447 nerve fiber data. These correlations are important in clinical routine especially when different techniques are used in the follow-up of @entity726 @entity1 .

title: Optical coherence tomography, scanning laser polarimetry and confocal scanning laser ophthalmoscopy in retinal nerve fiber layer measurements of XXXX @entity1 .

entities_list: @entity1538 :: ('MESH:D005902', 'Disease') :: ['open angle glaucoma']

entities_list: @entity726 :: ('MESH:D005901', 'Disease') :: ['glaucoma']

answer: @entity726 :: (MESH:D005901,Disease) :: ['glaucoma']


abstract: PURPOSE: To determine the correlations and strength of association between different imaging systems in analyzing the retinal nerve fiber layer (RNFL) of @entity726 @entity1 : optical coherence tomography ( @entity6653 ), scanning laser polarimetry (SLP) and confocal scanning laser ophthalmoscopy (CSLO). MATERIALS AND METHODOLOGY: 114 eyes of @entity1 with moderate @entity1538 underwent spectral domain @entity6653 (Topcon SD- @entity6653 2000 and Zeiss Cirrus HD- @entity6653 ), SLP ( @entity9999 Pro) and CSLO (Heidelberg Retina Tomograph, @entity12447 ). Correlation coefficients were calculated between the structural parameters yielded by these examinations. The quantitative relationship between the measured RNFL thickness globally and for the four regions (superior, inferior, nasal, temporal) were evaluated with different regression models for all used imaging systems. RESULTS: The strongest correlation of RNFL measurements was found between devices using the same technology like @entity9999 VCC and @entity9999 Pro as well as Topcon @entity6653 and Cirrus @entity6653 . In @entity726 @entity1 , the strongest associations (R  ) were found between RNFL measurements of the two optical coherence tomography devices Topcon @entity6653 and Cirrus @entity6653 (R   = 0.513) and between @entity9999 VCC and @entity9999 Pro (R   = 0.451). The results of the OCTs and @entity9999 Pro also had a strong quantitative relationship (Topcon @entity6653 R   = 0.339 and Cirrus @entity6653 R   = 0.347). @entity9999 VCC and the OCTs showed a mild to moderate association (Topcon @entity6653 R   = 0.207 and Cirrus @entity6653 R   = 0.258). The confocal scanning laser ophthalmoscopy ( @entity12447 ) had the lowest association to all other devices (Topcon @entity6653 R   = 0.254, Cirrus @entity6653 R   = 0.158, @entity9999 Pro R   = 0.086 and @entity9999 VCC R   = 0.1). CONCLUSION: The measurements of the RNFL in @entity726 @entity1 reveal a high correlation of @entity6653 and @entity9999 devices because OCTs can measure all major retinal layers and SLP can detect nerve fibers allowing a comparison between the results of this devices. However, CSLO by means of HRT topography can only measure height values of the retinal surface but it cannot distinguish between different retinal layers. This may explain the rather poor correlations and associations between CSLO measurements and those of all other imaging devices which makes it difficult to compare @entity12447 nerve fiber data. These correlations are important in clinical routine especially when different techniques are used in the follow-up of @entity726 @entity1 .

title: Optical coherence tomography, scanning laser polarimetry and confocal scanning laser ophthalmoscopy in retinal nerve fiber layer measurements of @entity726 XXXX .

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

answer: @entity1 :: (9606,Species) :: ['patients']


abstract: PURPOSE: To determine the role of @entity1 / @entity5 characteristics, radiation dose, and fractionation using the linear-quadratic (LQ) model to predict stereotactic body radiation therapy-induced grade >= 2 chest wall @entity158 (CWP2) in a larger series and develop clinically useful constraints for @entity1 treated with different fraction numbers. METHODS AND MATERIALS: A total of 316 @entity2 in 295 @entity1 were treated with  stereotactic body radiation therapy in 3 to 5 fractions to 39 to 60  Gy. Absolute dose-absolute volume chest wall (CW) histograms were acquired. The raw dose-volume histograms (a/b  =      Gy) were converted via the LQ model to equivalent doses in 2-Gy fractions (normalized total dose, NTD) with a/b from 0 to 25  Gy in 0.1-Gy steps. The Cox proportional hazards (CPH) model was used in univariate and multivariate models to identify and assess CWP2 exposed to a given physical and NTD. RESULTS: The median follow-up was 15.4  months, and the median time to development of CWP2 was 7.4  months. On a univariate CPH model, prescription dose, prescription dose per fraction, number of fractions, D83cc, distance of @entity5 to CW, and body mass index were all statistically significant for the development of CWP2. Linear-quadratic correction improved the CPH model significance over the physical dose. The best-fit a/b was 2.1  Gy, and the physical dose (a/b  =      Gy) was outside the upper 95% confidence limit. With a/b  =  2.1  Gy, VNTD99Gy was most significant, with median VNTD99Gy  =  31.5  cm(3) (hazard ratio 3.87, P<.001). CONCLUSION: There were several predictive factors for the development of CWP2. The LQ-adjusted doses using the best-fit a/b  =  2.1  Gy is a better predictor of CWP2 than the physical dose. To aid dosimetrists, we have calculated the physical dose equivalent corresponding to VNTD99Gy  =  31.5  cm(3) for the 3- to 5-fraction groups.

title: Impact of Fractionation and Dose in a Multivariate Model for Radiation-Induced Chest  Wall XXXX .

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'patient']

entities_list: @entity2 :: ('MESH:D008175', 'Disease') :: ['lung tumors']

answer: @entity158 :: (MESH:D010146,Disease) :: ['Pain']


abstract: OBJECTIVE: To compare the oncologic outcomes and prognostic factors between metastatic upper tract @entity189 (UTUC) and UC of the bladder (UCB) after @entity900 -based chemotherapy. MATERIALS AND METHODS: We retrospectively reviewed @entity1 with metastatic UTUC and UCB after @entity1499 / @entity5713 / @entity632 / @entity900 (MVAC) or @entity136 / @entity900 chemotherapy between 1997 and 2014 at Kaohsiung Chang Gung Memorial Hospital. Progression-free survival (PFS) and @entity1349 ( @entity1349 ) were estimated by the Kaplan-Meier method. Univariate and multivariate analyses with Cox proportional hazard models were also performed to assess the effect of prognostic factors. RESULTS: Totally, 203 @entity1 were enrolled into our study, including 120 @entity1 with UTUC and 83 @entity1 with UCB. For @entity1 with UTUC, the median PFS was 7.3 months vs. 4.0 months (P<0.001), and the median @entity1349 was 17.0 months vs. 10.5 months (P<0.001) for MVAC and @entity136 / @entity900 , respectively. For @entity1 with UCB, the median PFS (P = 0.35) and @entity1349 (P = 0.06) of the 2 groups were insignificant. In multivariate analyses, number of metastatic sites was the identical prognostic factor for @entity1349 between UTUC (hazard ratio [HR] = 2.74; 95% CI: 1.63-4.62; P<0.001) and UCB (HR = 3.12; 95% CI: 1.52-6.39; P = 0.002). Presence of liver @entity3 (HR = 1.84; 95% CI: 1.05-2.23; P = 0.03) and MVAC chemotherapy (HR = 0.54; 95% CI: 0.35-0.83; P<0.001) were significantly correlated to survival only for UTUC, not for UCB. CONCLUSION: Our study suggests discordant oncologic outcomes and prognostic factors between metastatic UTUC and UCB after @entity900 -based chemotherapy. A prospective study is warranted to validate our results.

title: The comparison of oncologic outcomes between metastatic upper tract @entity189 and @entity189 of the bladder after XXXX -based chemotherapy.

entities_list: @entity632 :: ('MESH:D004317', 'Chemical') :: ['doxorubicin']

entities_list: @entity900 :: ('MESH:D002945', 'Chemical') :: ['cisplatin']

entities_list: @entity189 :: ('MESH:D002277', 'Disease') :: ['urothelial carcinoma']

entities_list: @entity1349 :: ('MESH:D011475', 'Disease') :: ['OS', 'overall survival']

entities_list: @entity3 :: ('MESH:D009362', 'Disease') :: ['metastasis']

entities_list: @entity1499 :: ('MESH:D008727', 'Chemical') :: ['methotrexate']

entities_list: @entity136 :: ('MESH:C056507', 'Chemical') :: ['gemcitabine']

entities_list: @entity5713 :: ('MESH:D014747', 'Chemical') :: ['vinblastine']

answer: @entity900 :: (MESH:D002945,Chemical) :: ['cisplatin']


abstract: OBJECTIVE: To compare the oncologic outcomes and prognostic factors between metastatic upper tract @entity189 (UTUC) and UC of the bladder (UCB) after @entity900 -based chemotherapy. MATERIALS AND METHODS: We retrospectively reviewed @entity1 with metastatic UTUC and UCB after @entity1499 / @entity5713 / @entity632 / @entity900 (MVAC) or @entity136 / @entity900 chemotherapy between 1997 and 2014 at Kaohsiung Chang Gung Memorial Hospital. Progression-free survival (PFS) and @entity1349 ( @entity1349 ) were estimated by the Kaplan-Meier method. Univariate and multivariate analyses with Cox proportional hazard models were also performed to assess the effect of prognostic factors. RESULTS: Totally, 203 @entity1 were enrolled into our study, including 120 @entity1 with UTUC and 83 @entity1 with UCB. For @entity1 with UTUC, the median PFS was 7.3 months vs. 4.0 months (P<0.001), and the median @entity1349 was 17.0 months vs. 10.5 months (P<0.001) for MVAC and @entity136 / @entity900 , respectively. For @entity1 with UCB, the median PFS (P = 0.35) and @entity1349 (P = 0.06) of the 2 groups were insignificant. In multivariate analyses, number of metastatic sites was the identical prognostic factor for @entity1349 between UTUC (hazard ratio [HR] = 2.74; 95% CI: 1.63-4.62; P<0.001) and UCB (HR = 3.12; 95% CI: 1.52-6.39; P = 0.002). Presence of liver @entity3 (HR = 1.84; 95% CI: 1.05-2.23; P = 0.03) and MVAC chemotherapy (HR = 0.54; 95% CI: 0.35-0.83; P<0.001) were significantly correlated to survival only for UTUC, not for UCB. CONCLUSION: Our study suggests discordant oncologic outcomes and prognostic factors between metastatic UTUC and UCB after @entity900 -based chemotherapy. A prospective study is warranted to validate our results.

title: The comparison of oncologic outcomes between metastatic upper tract XXXX and @entity189 of the bladder after @entity900 -based chemotherapy.

answer: @entity189 :: (MESH:D002277,Disease) :: ['urothelial carcinoma']


abstract: OBJECTIVE: To compare the oncologic outcomes and prognostic factors between metastatic upper tract @entity189 (UTUC) and UC of the bladder (UCB) after @entity900 -based chemotherapy. MATERIALS AND METHODS: We retrospectively reviewed @entity1 with metastatic UTUC and UCB after @entity1499 / @entity5713 / @entity632 / @entity900 (MVAC) or @entity136 / @entity900 chemotherapy between 1997 and 2014 at Kaohsiung Chang Gung Memorial Hospital. Progression-free survival (PFS) and @entity1349 ( @entity1349 ) were estimated by the Kaplan-Meier method. Univariate and multivariate analyses with Cox proportional hazard models were also performed to assess the effect of prognostic factors. RESULTS: Totally, 203 @entity1 were enrolled into our study, including 120 @entity1 with UTUC and 83 @entity1 with UCB. For @entity1 with UTUC, the median PFS was 7.3 months vs. 4.0 months (P<0.001), and the median @entity1349 was 17.0 months vs. 10.5 months (P<0.001) for MVAC and @entity136 / @entity900 , respectively. For @entity1 with UCB, the median PFS (P = 0.35) and @entity1349 (P = 0.06) of the 2 groups were insignificant. In multivariate analyses, number of metastatic sites was the identical prognostic factor for @entity1349 between UTUC (hazard ratio [HR] = 2.74; 95% CI: 1.63-4.62; P<0.001) and UCB (HR = 3.12; 95% CI: 1.52-6.39; P = 0.002). Presence of liver @entity3 (HR = 1.84; 95% CI: 1.05-2.23; P = 0.03) and MVAC chemotherapy (HR = 0.54; 95% CI: 0.35-0.83; P<0.001) were significantly correlated to survival only for UTUC, not for UCB. CONCLUSION: Our study suggests discordant oncologic outcomes and prognostic factors between metastatic UTUC and UCB after @entity900 -based chemotherapy. A prospective study is warranted to validate our results.

title: The comparison of oncologic outcomes between metastatic upper tract @entity189 and XXXX of the bladder after @entity900 -based chemotherapy.

answer: @entity189 :: (MESH:D002277,Disease) :: ['urothelial carcinoma']


abstract: BACKGROUND: Surgical site infections (SSIs) are wound infections that occur after invasive (surgical) procedures. Preoperative bathing or showering with an antiseptic skin wash product is a well-accepted procedure for reducing skin bacteria (microflora). It is less clear whether reducing skin microflora leads to a lower incidence of @entity281 . OBJECTIVES: To review the evidence for preoperative bathing or showering with antiseptics for preventing hospital-acquired (nosocomial) surgical site infections. SEARCH METHODS: For this fifth update we searched the Cochrane Wounds Group Specialised Register (searched 18 December 2014); the Cochrane Central Register of Controlled Trials (The Cochrane Library 2014 Issue 11); Ovid MEDLINE (2012 to December Week 4 2014), Ovid MEDLINE (In-Process _ Other Non-Indexed Citations December 18, 2014); Ovid EMBASE (2012 to 2014 Week 51), EBSCO CINAHL (2012 to December 18 2014) and reference lists of articles. SELECTION CRITERIA: Randomised controlled trials comparing any antiseptic preparation used for preoperative full-body bathing or showering with non-antiseptic preparations in @entity1 undergoing surgery. DATA COLLECTION AND ANALYSIS: Two review authors independently assessed studies for selection, risk of bias and extracted data. Study authors were contacted for additional information. MAIN RESULTS: We did not identify any new trials for inclusion in this fifth update. Seven trials involving a total of 10,157 @entity1 were included. Four of the included trials had three comparison groups. The antiseptic used in all trials was 4% @entity5164 (Hibiscrub/Riohex). Three trials involving 7791 @entity1 compared @entity1216 with a placebo. Bathing with @entity1216 compared with placebo did not result in a statistically significant reduction in SSIs; the relative risk of SSI (RR) was 0.91 (95% confidence interval (CI) 0.80 to 1.04). When only trials of high quality were included in this comparison, the RR of SSI was 0.95 (95%CI 0.82 to 1.10). Three trials of 1443 @entity1 compared bar soap with @entity1216 ; when combined there was no difference in the risk of SSIs (RR 1.02, 95% CI 0.57 to 1.84). Three trials of 1192 @entity1 compared bathing with @entity1216 with no washing, one large study found a statistically significant difference in favour of bathing with @entity1216 (RR 0.36, 95%CI 0.17 to 0.79). The smaller studies found no difference between @entity1 who washed with @entity1216 and those who did not wash preoperatively. AUTHORS' CONCLUSIONS: This review provides no clear evidence of benefit for preoperative showering or bathing with @entity1216 over other wash products, to reduce @entity281 . Efforts to reduce the incidence of nosocomial @entity281 should focus on interventions where effect has been demonstrated.

title: Preoperative bathing or showering with skin antiseptics to prevent XXXX .

entities_list: @entity1 :: ('9606', 'Species') :: ['participants', 'patients', 'people']

entities_list: @entity281 :: ('MESH:D007239', 'Disease') :: ['surgical site infection']

entities_list: @entity1216 :: ('MESH:D002710', 'Chemical') :: ['chlorhexidine']

entities_list: @entity5164 :: ('MESH:C010882', 'Chemical') :: ['chlorhexidine gluconate']

answer: @entity281 :: (MESH:D007239,Disease) :: ['surgical site infection']


abstract: OBJECTIVE: To explore the best time of intratympanic @entity619 injection to treat @entity1274 ( @entity1274 ) as salvage therapy so that to improve the curative efficacy on sudden @entity2319 at the utmost. METHOD: A total of 192 @entity1 with @entity1274 were included in this study, among whom 63 cases received the systemic @entity479 therapy throughout the study, while the other ones were treated with systemic @entity479 as initial treatment and were given intratympanic @entity479 administration as salvage treatment starting at different time point. The salvage treatment started on the 3rd day after the beginning of the initial treatment for 29 cases, on the 7th day for 38 cases, on the 14th day for 43 cases, and 1 month later for 19 cases. All the @entity1 were followed up for 2 months. RESULT: The recovery rates and total effective rates showed no statistically significant difference between the @entity1 received only systemic @entity479 therapy and the ones received intratympanic @entity479 administration on the 3rd, 7th day and 1 month later after the initial treatment. The recovery rate and total effective rate exhibited statistically significant difference between the @entity1 received intratympanic @entity479 administration since the 14th day after the initial treatment and the ones received only systemic @entity479 therapy, with the numerical value of P 0. 037 and 0. 034, respectively. CONCLUSION: (1) As an initial management plan, the curative effects. between the intratympanic @entity479 administration and the systemic @entity479 therapy were not significantly different. (2) As a salvage treatment, intratympanic @entity479 was a better choice for @entity1 who have not completely recover from ISSNHL after failure of initial management with systemic @entity479 only. (3) The best time point of salvage treatment with intratympanic @entity479 was about 2 weeks after initial management with systemic @entity479 .

title: [Time of salvage treatment on XXXX ].

entities_list: @entity619 :: ('MESH:D003907', 'Chemical') :: ['dexamethasone']

entities_list: @entity1274 :: ('MESH:D006319', 'Disease') :: ['SSNHL', 'sudden sensorineural hearing loss']

answer: @entity1274 :: (MESH:D006319,Disease) :: ['sudden sensorineural hearing loss']